Welcome to our dedicated page for CRXTW news (Ticker: CRXTW), a resource for investors and traders seeking the latest updates and insights on CRXTW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRXTW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRXTW's position in the market.
Clarus Therapeutics Holdings has filed for Chapter 11 bankruptcy, seeking to auction its primary asset, JATENZO, a testosterone treatment. The company aims to maintain operations during this process and believes it has enough financial resources to meet obligations. Clarus’s leadership expressed that a structured sale is necessary due to financial challenges, despite JATENZO's potential market value. Interested buyers can bid on the assets through a court-approved process, which is expected to conclude by late October 2022.
Clarus Therapeutics Holdings reported a 46% year-over-year increase in net revenue for Q2 2022, reaching $4.1 million. Prescription growth for JATENZO surged 72% year-over-year. However, the company announced a 40% workforce reduction to evaluate strategic alternatives, impacting their operational structure. Clarus faced a net loss of $10.7 million for the quarter, raising concerns about its ability to continue as a going concern. Cash reserves stood at $19.2 million as of June 30, 2022, with significant debt.
Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT) announced a notice of allowance from the USPTO for additional patent claims covering its oral testosterone replacement therapy, JATENZO (testosterone undecanoate). This patent, set to expire in 2030, will be the ninth patent for JATENZO listed in the FDA’s Orange Book. Dr. Robert Dudley, CEO, highlighted the strategic investment in JATENZO's intellectual property. Male hypogonadism affects an estimated 20 million men in the U.S., with JATENZO providing a treatment option for this condition.
Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) will present new data for JATENZO (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s annual meeting, scheduled for June 11-14, 2022, in Atlanta. The presentation, titled Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone, is set for June 13, 2022. JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in men with deficient testosterone levels due to medical conditions, potentially affecting 20 million men in the U.S.
Clarus Therapeutics announced the issuance of a new patent for JATENZO, its oral testosterone replacement therapy, by the USPTO. Patent No. 11,331,325 enhances the company’s intellectual property portfolio, now totaling eight patents listed in the FDA's Orange Book, with the latest patent expiring in January 2027. JATENZO addresses male hypogonadism, a condition affecting approximately 20 million men in the U.S. This development supports Clarus' strategy to protect and expand market opportunities for JATENZO.
Clarus Therapeutics (Nasdaq: CRXT) reported a 72% increase in net revenue for Q1 2022, totaling $4.0 million compared to $2.3 million last year. Total prescriptions for JATENZO® rose by 12% sequentially and 75% year-over-year. The company closed a $30 million public offering, extending its cash runway. Operating expenses increased by 33% to $16.9 million, while the net loss was $14.9 million, or $0.61 per share. Major clinical trials for JATENZO and CLAR-121 are anticipated in the second half of 2022.
Clarus Therapeutics Holdings (Nasdaq: CRXT) announced it will release its Q1 2022 financial results on May 16, 2022, after market close. A conference call is scheduled for the same day at 5:15 p.m. ET, where investors can discuss the results. Domestic callers can dial (844) 249-2007 and international callers can use (224) 619-3902, using conference ID 7677008. Clarus specializes in androgen and metabolic therapies, with its first product being JATENZO® (testosterone undecanoate). More details can be found on their investor website.
Clarus Therapeutics Holdings announced a notice of allowance from the USPTO for its patent on CLAR-121, a treatment for autoimmune inflammatory mastitis. The U.S. patent is set to expire in June 2040. The company aims to obtain Orphan Drug Designation from the FDA for CLAR-121, focusing on periductal mastitis (PDM), affecting around 150,000 women in the U.S. annually. Clarus plans to initiate a Phase 2 clinical trial in the second half of 2022, pending funding. The patent supports a novel approach to treating this painful condition without effective drug interventions.
Clarus Therapeutics Holdings (Nasdaq: CRXT) announced new data for JATENZO (testosterone undecanoate) will be presented at the 2022 American Urological Association Annual Meeting in New Orleans from May 13-16, 2022. The abstract, titled Linear Relationship between the Time of Dosing and 24-Hour Average Concentration of Total Testosterone, will be presented on May 14 at 4:30 p.m. CT. Male hypogonadism affects 20 million men in the U.S., with treatment options including testosterone replacement therapy.
Clarus Therapeutics has received a notice of allowance from the USPTO for a new patent covering its testosterone replacement therapy, JATENZO. The patent, which will be listed in the FDA’s Orange Book, adds to the existing seven patents already covering the product, extending its market exclusivity. JATENZO is the first FDA-approved oral softgel for testosterone therapy, targeting the approximately 20 million men in the U.S. with hypogonadism. The new patent is set to expire in 2026, enhancing the intellectual property portfolio of the company.
